TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Wolf Haldenstein Adler Freeman & Herz Llp
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

Telix Pharmaceuticals is under investigation by the SEC for potential misrepresentations about its prostate cancer therapeutic candidates and drug pipeline, leading to significant stock price declines.

Insights
AMD   neutral

Mentioned as a competitor to Nvidia in the GPU market, but no specific performance details were provided


TLX   negative

Company faced SEC subpoena, stock price dropped multiple times due to disclosure concerns about drug pipeline, and potential misrepresentation of progress in prostate cancer therapeutic candidates